Spots Global Cancer Trial Database for epithelioid sarcoma
Every month we try and update this database with for epithelioid sarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | NCT03190174 | Ewing Sarcoma PEComa Epithelioid Sar... Desmoid Tumor Chordoma Non Small Cell ... Urothelial Carc... Melanoma Renal Cell Carc... Squamous Cell C... Hepatocellular ... Classical Hodgk... Colorectal Canc... MTOR Activating... | Nab-Rapamycin Nivolumab | 12 Years - | Sarcoma Oncology Research Center, LLC | |
| Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma | NCT04225429 | Epithelioid Sar... | Tazemetostat | 18 Years - | Ipsen | |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | NCT04996004 | Leiomyosarcoma | Ontorpacept (TT... Doxorubicin | 18 Years - | Pfizer | |
| Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients | NCT04008238 | Soft Tissue Sar... Undifferentiate... Epithelioid Sar... Solitary Fibrou... Hemangioendothe... Desmoplastic Ro... Synovial Sarcom... | Trabectedin | 18 Years - | Institut Bergonié | |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Sarcoma | pegfilgrastim doxorubicin hyd... ifosfamide pegylated lipos... conventional su... fludeoxyglucose... | 16 Years - | Masonic Cancer Center, University of Minnesota | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | NCT06277154 | Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm... | MASCT-I Doxorubicin Ifosfamide | 18 Years - 70 Years | HRYZ Biotech Co. | |
| Irinotecan and Anlotinib for Epithelioid Sarcoma | NCT05656222 | Objective Respo... Overall Surviva... | VIA combination... | 3 Years - | Peking University People's Hospital | |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | NCT04996004 | Leiomyosarcoma | Ontorpacept (TT... Doxorubicin | 18 Years - | Pfizer | |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Sarcoma | pegfilgrastim doxorubicin hyd... ifosfamide pegylated lipos... conventional su... fludeoxyglucose... | 16 Years - | Masonic Cancer Center, University of Minnesota | |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | NCT02180867 | Alveolar Soft P... Angiomatoid Fib... Atypical Fibrox... Clear Cell Sarc... Epithelioid Mal... Epithelioid Sar... Extraskeletal M... Extraskeletal O... Fibrohistiocyti... Fibrosarcoma Inflammatory My... Intimal Sarcoma Leiomyosarcoma Liposarcoma Liver Embryonal... Low Grade Fibro... Low Grade Myofi... Malignant Cutan... Malignant Perip... Malignant Trito... Mesenchymal Cho... Myxofibrosarcom... Myxoid Chondros... Myxoinflammator... Nerve Sheath Ne... PEComa Pericytic Neopl... Plexiform Fibro... Sclerosing Epit... Skin Glomus Tum... Stage IB Soft T... Stage IIB Soft ... Stage III Soft ... Stage IV Soft T... Synovial Sarcom... Undifferentiate... | Doxorubicin Doxorubicin Hyd... Ifosfamide Pazopanib Pazopanib Hydro... Radiation Thera... Therapeutic Con... | 2 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | NCT02180867 | Alveolar Soft P... Angiomatoid Fib... Atypical Fibrox... Clear Cell Sarc... Epithelioid Mal... Epithelioid Sar... Extraskeletal M... Extraskeletal O... Fibrohistiocyti... Fibrosarcoma Inflammatory My... Intimal Sarcoma Leiomyosarcoma Liposarcoma Liver Embryonal... Low Grade Fibro... Low Grade Myofi... Malignant Cutan... Malignant Perip... Malignant Trito... Mesenchymal Cho... Myxofibrosarcom... Myxoid Chondros... Myxoinflammator... Nerve Sheath Ne... PEComa Pericytic Neopl... Plexiform Fibro... Sclerosing Epit... Skin Glomus Tum... Stage IB Soft T... Stage IIB Soft ... Stage III Soft ... Stage IV Soft T... Synovial Sarcom... Undifferentiate... | Doxorubicin Doxorubicin Hyd... Ifosfamide Pazopanib Pazopanib Hydro... Radiation Thera... Therapeutic Con... | 2 Years - | National Cancer Institute (NCI) | |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | NCT05415098 | Nasopharyngeal ... Castrate Resist... Gastric Cancer Ovarian Clear C... Mesothelioma Sarcoma Non Hodgkin Lym... B Cell Lymphoma Epithelioid Sar... | APG-5918 | 18 Years - | Ascentage Pharma Group Inc. | |
| Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma | NCT04225429 | Epithelioid Sar... | Tazemetostat | 18 Years - | Ipsen | |
| A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors | NCT05355753 | Synovial Sarcom... Soft Tissue Sar... | CFT8634 | 12 Years - | C4 Therapeutics, Inc. | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | NCT06277154 | Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm... | MASCT-I Doxorubicin Ifosfamide | 18 Years - 70 Years | HRYZ Biotech Co. | |
| Epithelioid Sarcoma Natural History Study | NCT03837678 | Epithelioid Sar... | 10 Years - | Ipsen | ||
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | NCT02584309 | Sarcoma, Soft T... Soft Tissue Sar... Undifferentiate... Leiomyosarcoma Liposarcoma Synovial Sarcom... Myxofibrosarcom... Angiosarcoma Fibrosarcoma Malignant Perip... Epithelioid Sar... | Dexrazoxane Doxorubicin | 18 Years - | Washington University School of Medicine | |
| FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | NCT04965753 | Advanced Synovi... | FHD-609 | 16 Years - | Foghorn Therapeutics Inc. | |
| A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | NCT03069378 | Sarcoma Epithelioid Sar... Cutaneous Angio... | Talimogene Lahe... Pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | NCT04996004 | Leiomyosarcoma | Ontorpacept (TT... Doxorubicin | 18 Years - | Pfizer | |
| Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | NCT05407441 | Atypical Terato... INI1 (SMARCB1)-... SMARCA4-deficie... Malignant Rhabd... Rhabdoid Tumor ... Epithelioid Sar... Chordoma | Tazemetostat Nivolumab Ipilimumab | 6 Months - 21 Years | Dana-Farber Cancer Institute | |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | NCT05415098 | Nasopharyngeal ... Castrate Resist... Gastric Cancer Ovarian Clear C... Mesothelioma Sarcoma Non Hodgkin Lym... B Cell Lymphoma Epithelioid Sar... | APG-5918 | 18 Years - | Ascentage Pharma Group Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
